Table of Contents
HPB Surgery
Volume 2, Issue 1, Pages 21-28

Hepatic Artery Infusion Chemotherapy

11st Dept. of Surgery, Rudolfstiftung, Vienna, Australia
21st Dept. of Internal Medicine, Rudolfstiftung, Vienna, Australia
3Institute of Nuclear Medicine, Rudolfstiftung, Vienna, Australia
41st Dept. of Surgery, Rudolfstiftung, Juchgasse 25, Vienna A-1030, Australia

Received 29 November 1988; Accepted 21 March 1989

Copyright © 1990 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hepatic artery chemotherapy was given to 36 patients, using totally implantable devices consisting of a port and external pump. Twenty-seven patients had inoperable liver metastases of colorectal origin. The infusion system was inserted by laparotomy into the hepatic artery via the gastroduodenal artery. There was no operative mortality. Thirteen infusion systems could not be used for chemotherapy due to dislodgement, early death and lack of follow-up. FUdR was infused every two weeks. There were minor local complications like thrombosis of the system and dislodgement of the port. Toxic effects could be managed by reducing the dose. Response to chemotherapy was evaluated by survival, clinical condition, CEA, ultrasound and CT six months after onset of arterial chemotherapy. Ten/twenty-three patients (43%) responded to therapy, eight of them died on the average 19 months after initial chemotherapy. Six patients were non-responders, seven had stable disease. Five/ten patients developed extrahepatic metastases. Mean survival time was 13.1 months, mean interval until relapse 10.6 months.